JMP Securities downgraded T-cell therapy developer Adicet Bio (NASDAQ:ACET) to market perform and removed its price target of $19, citing uncertainty about the start date for a pivotal study for the ...

PHILADELPHIA--Analyzing data from clinical trials and genomics research becomes faster and easier this summer with new versions of JMP Clinical and JMP Genomics. Both desktop products link interactive ...

On Wednesday, JMP Securities adjusted its share price target for Crinetics Pharmaceuticals (NASDAQ:CRNX), increasing it to $80 from the previous $60, while maintaining a Market Outperform rating. This ...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc.